Population Groups: Clinical Trials

29 trials of Population Groups, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 5 unknown, 4 not yet recruiting, 2 recruiting. 29 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 429Completed 15, Unknown 5, Not yet recruiting 4, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Population Groups: new trials by email Literature Review of Population Groups trials Research Report on Population Groups

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy Comparison of 10-Day High-Dose Versus 14-Day Standard-Dose Vonoprazan Plus Amoxicillin in Helicobacter Pylori Eradication: A Multicenter Non-Inferiority Randomized Controlled Trial
10-day group, 14-day group - Helicobacter Infection, Vonoprazan
Phase 4Not yet recruitingShandong University2322026-09-302026-09-29
Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Patients Undergoing Laparoscopic Hepatectomy
Anruikefon 1 μg/kg per dose Group, Anruikefon 100 μg per dose Group, Control group - Postoperative Acute Pain
Phase 4Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University1172026-08-302026-09-03
Comparison of the Analgesic Efficacy of Ultrasound-guided Retrolaminar Block Versus Serratus Anterior Plane Block in Patients Undergoing Radical Mastectomy
Serratus Anterior Plane Block (SAPB) group, Retrolaminar block group - Serratus Anterior Plane Block
Phase 4CompletedAin Shams University902026-05-172026-11-04
Dose-escalation of Rectal Indomethacin for Preventing PEP
standard-dose group VS high-dose group - Post-ERCP Pancreatitis
Phase 4Not yet recruitingThe First Affiliated Hospital of Anhui Medical University10362025-12-012025-11-25
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group - Ischemic Stroke Hospitalized, Impairment, Cognitive
Phase 4Active not recruitingDr. Willmar Schwabe GmbH & Co. KG4002025-11-282026-10-30
Methadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study
Methadone, Placebo - Post Operative Pain, Spinal Surgery
Phase 4RecruitingThe Cleveland Clinic1202025-11-152025-12-17
Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial(HERO -aCKD)
Henagliflozin 5 mg Group, Henagliflozin 10 mg Group, Conventional therapy group - Chronic Kidney Disease Stage 4
Phase 4Not yet recruitingFirst Affiliated Hospital of Wannan Medical College4292025-07-102025-06-18
Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery
Tranexamic acid bolus 20 mg/kg, Tranexamic acid bolus 10 mg/kg, Tranexamic acid bolus 1 mg/kg - Antifibrinolytic Agents
Phase 4RecruitingInsel Gruppe AG, University Hospital Bern3222023-12-152025-06-06
Hemodynamic Response to Pain During Retinopathy Of Prematurity Screening
benoxinate hydrochloride 0.4% group, saline 0.9% . - Preterm
Phase 4CompletedAlexandria University682023-01-202025-02-05
Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults
Remimazolam Tosilate for Injection 0.1mg/kg, Remimazolam Tosilate for Injection 0.15mg/kg, Remimazolam Tosilate for Injection 0.2mg/kg - Hypotension During Surgery
Phase 4CompletedTongji Hospital6502021-07-012025-06-29
Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy
Nepafenac 0.1% eyedrops, Control (placebo) group - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Phase 4CompletedUniversitas Indonesia612021-04-282025-09-09
The Potential Benefit of Xiao-Yao-San Treatment in Patients With Insomnia
Xiao-Yao-San, Weight loss class(WLC) group - Treatment
Phase 4CompletedYu-Ching HSU192019-01-012024-10-24
Antibacterial-coated Sutures at Time of Cesarean
Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures), Vicryl, monocryl, PDS (not coated with triclosan) - Surgical Site Infection, Surgical Wound Infection
Phase 4TerminatedThe University of Texas Medical Branch, Galveston11692018-01-092026-06-22
Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
Standard Dose Group, Weight Based Group - Obesity
Phase 4WithdrawnUniversity of Colorado, Denver2017-09-012017-12-06
Gabapentin as Preanesthetic Medication to Fast Procedures in Pediatric´s Oncology
Placebo Group, GABA 15mg/kg Group, GABA 30mg/kg Group - Pain, Postoperative, Agitation States as Acute Reaction to Exceptional Stress
Phase 4CompletedHospital Infantil Albert Sabin1352017-07-012018-09-27
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)
Enoxaparin (Staged-dose PCI Group), Enoxaparin (Single-dose PCI Group), Enoxaparin (High-dose Group) - Coronary Artery Disease, Percutaneous Coronary Intervention
Phase 4CompletedPeking Union Medical College Hospital3782017-05-122022-10-12
Effect of Hyperuricaemia on Chronic Renal Disease
20mg Febuxostat, 40mg Febuxostat - Hyperuricemia, Chronic Renal Disease
Phase 4UnknownThe Affiliated Hospital of Xuzhou Medical University4002017-01-012018-02-07
Effect of Rosuvastatin Therapy on HDL2 Level
Rosuvastatin 10mg/d group, Rosuvastatin 20mg/d group - Hyperlipemia, Coronary Heart Disease
Phase 4UnknownDaping Hospital and the Research Institute of Surgery of the Third Military Medical University3002015-11-012015-11-03
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
Rosuvastatin 5mg, Rosuvastatin 20mg - Coronary Artery Disease, Coronary Disease
Phase 4UnknownKorea University Anam Hospital3002015-09-012016-08-09
P. Falciparum Resistance to Artemisinin in Vietnam
Artesunate (AS) group, DHA - PPQ group - Drug Resistant Malaria Due to Plasmodium Falciparum
Phase 4UnknownNational Institute of Malariology, Parasitology and Entomology, Vietnam1202015-04-012015-12-21

Showing 20 of 29. Sign in to see all of them.

Conditions studied

Pain, Postoperative (4)  ·  Coronary Artery Disease (3)  ·  Coronary Disease (2)  ·  Hyperlipidemias (2)  ·  Renal Insufficiency, Chronic (2)  ·  Atherosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Cognitive Dysfunction (1)  ·  Depressive Disorder, Major (1)  ·  Dyslipidemias (1)  ·  Epilepsy (1)  ·  Helicobacter Infections (1)  ·  Hyperphagia (1)  ·  Hyperuricemia (1)  ·  Hypotension (1)

Sponsors

University of Colorado, Denver (2)  ·  Ain Shams University (1)  ·  Alexandria University (1)  ·  Daewoong Pharmaceutical Co. LTD. (1)  ·  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1)  ·  Dr. Willmar Schwabe GmbH & Co. KG (1)  ·  Eisai Korea Inc. (1)  ·  First Affiliated Hospital of Wannan Medical College (1)  ·  Hospital Infantil Albert Sabin (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Korea University Anam Hospital (1)  ·  Kuopio University Hospital (1)  ·  National Institute of Malariology, Parasitology and Entomology, Vietnam (1)  ·  National Taiwan University Hospital (1)  ·  Northwestern University (1)

Countries

China (7)  ·  United States (5)  ·  South Korea (3)  ·  Egypt (2)  ·  Taiwan (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Finland (1)  ·  France (1)  ·  Indonesia (1)  ·  Switzerland (1)  ·  Vietnam (1)

Top investigators

Ailin Luo, Doctor (1)  ·  Andra Duncan, MD (1)  ·  Anna Rosanas-Urgell, MD, PhD (1)  ·  Annegret Kauert-Willms, MD (1)  ·  Ari Djatikusumo, MD (1)  ·  Benjamin Bush, M.D. (1)  ·  Changzhen Shang (1)  ·  Do-sun Lim, MD, PhD (1)  ·  Dong Sun, MD (1)  ·  Duong Tran, MD, PhD (1)  ·  Herbert Meltzer, M.D. (1)  ·  Hesham Ghazal, PhD (1)  ·  Hyung Joon Joo, MD, PhD (1)  ·  Jihee Mun (1)  ·  Joon Pio Hong, MD (1)

Results publications

PMID 11011804, PMID 11156876, PMID 11181470, PMID 11287711, PMID 12147872, PMID 12475453, PMID 12575964, PMID 12644342, PMID 12845386, PMID 14755805, PMID 15249498, PMID 15383472, PMID 1595522, PMID 16187968, PMID 16957147, PMID 17296821, PMID 17368152, PMID 17898099, PMID 18276619, PMID 18955731, PMID 19332455, PMID 19463333, PMID 20170785, PMID 20418301, PMID 20466199, PMID 21544927, PMID 21777368, PMID 21856483, PMID 22070834, PMID 22306479, PMID 22584085, PMID 22922414, PMID 23428644, PMID 23753843, PMID 23968700, PMID 24211309, PMID 24247671, PMID 24465490, PMID 24528685, PMID 24595147, PMID 24677734, PMID 24739590, PMID 24952056, PMID 25075159, PMID 25173339, PMID 25179260, PMID 25230144, PMID 25249586, PMID 25791214, PMID 25792206